We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Ultrasound as Effective as Surgery for Prostate Cancer

By HospiMedica International staff writers
Posted on 19 Jul 2018
A new study suggests that high-intensity focused ultrasound (HIFU) can destroy prostate cancer (PC) tumors as efficiently as surgery or radiotherapy (RT), but with fewer side effects.

Researchers at Imperial College London (Imperial; United Kingdom), University College London (UCL, United Kingdom), and other institutions conducted a prospective study of 625 consecutive patients with non-metastatic, clinically significant PC who underwent focal HIFU between January 1, 2006 and December 31, 2015. More...
Disease was first localized using multiparametric magnetic resonance imaging (mpMRI), combined with targeted systematic biopsies, or transperineal mapping biopsies.

Areas of significant disease were treated, with follow-up including prostate-specific antigen (PSA) measurement, mpMRI, and biopsy. The primary endpoint, failure-free survival (FFS), was defined as freedom from radical or systemic therapy, metastases, and cancer-specific mortality after five years. During median follow-up of 56 months, high-risk PC was found in 505 patients (84%). FFS was 99% at one year, 92% at 3 years, and 88% at 5 years. For the whole patient cohort, metastasis-free, cancer-specific, and overall survival at five years was 98%, 100%, and 99% respectively.

The results confirmed that cancer survival rate from HIFU was 100%, identical to that of surgery and RT. The study showed, however, that the risk of side effects when HIFU was used was lower than the risk incurred by the other treatment options. Urinary incontinence affected two percent of patients, but none required more than one pad per day. Erectile dysfunction affected 15% of the study population. The study was published on June 27, 2018, in European Urology.

“Although prostate cancer survival rates are now very good, the side effects of surgery or radiotherapy can be life-changing. Some patients are left requiring multiple incontinence pads every day, or with severe erectile dysfunction,” said lead author Professor Hashim Ahmed, PhD, of Imperial. “We need to now focus on improving the quality of life for these men following treatment. This latest trial of focal HIFU suggests we may be able to tackle the cancer with fewer side effects.”

HIFU technology is based on nonlinear acoustic mathematical optimization methods to analyze and simulate the propagation of sound in material. The information is then used to enhance the shape of an acoustic lens so that that ultrasound pressure is focused precisely on the location of the tissue to be ablated, while the surrounding tissue retains as little damage as possible.

Related Links:
Imperial College London
University College London


Gold Member
Blood Gas Analyzer
i-Check200
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Resorbable Bovine Collagen Membrane
GenDerm
Tourniquet System
heidi– mein Tourniquet
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Illustration of the Hēlo Thrombectomy System device (Photo courtesty of Endovascular Engineering)

FDA-Cleared Thrombectomy System Removes Pulmonary Embolism Clots

Pulmonary embolism occurs when blood clots travel to the lungs and block blood flow, potentially requiring urgent endovascular intervention to prevent death. Catheter-based clot removal can be challenging,... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: Steris is expanding its healthcare consumables portfolio through an agreement to acquire Xodus Medical, a surgical products business focused on patient and operating room staff safety.

Steris to Expand Surgical Safety Portfolio With $2.1 Billion Xodus Medical Deal

Steris has signed a definitive agreement to acquire Xodus Medical, a specialty surgical products business based in Pennsylvania, for $2.1 billion at closing. The acquisition will expand Steris’s healthcare... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.